Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Neoplasms 3 Stomach Neoplasms 2 Neoplasms 2 Esophageal Neoplasms 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Peritoneal Neoplasms 1 Pelvic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Appendiceal Neoplasms 1

Interventions

Paclitaxel 42 Carboplatin 35 pembrolizumab 25 Surveys and Questionnaires 23 Letrozole 15 Radiotherapy 14 Megestrol Acetate 14 Blood Specimen Collection 14 Bevacizumab 13 olaparib 12 Metformin 12 dostarlimab 10 Indocyanine Green 10 durvalumab 9 Observation 9 Medroxyprogesterone Acetate 9 Cisplatin 9 lenvatinib 8 atezolizumab 8 Magnetic Resonance Spectroscopy 8 Everolimus 8 Early Intervention, Educational 8 Counseling 8 niraparib 7 Specimen Handling 7 Sentinel Lymph Node Biopsy 7 Radiation 7 Methods 7 Lymph Node Excision 7 Hysterectomy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Endometrial Neoplasms × Pafolacianine × Clear all

NCT07278986 2025-12-12

CYTALUX ISS

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡